Close
Achema middle east
swop processing & packaging

EMA approves Genzyme Framingham manufacturing plant

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

LTS Grows U.S. Footprint by Buying CDMO Renaissance Lakewood

As the U.S. production investments continue to roll in...

AstraZeneca Plant Expansion to Double Production of Lokelma

AstraZeneca has gone on to announce a newly expanded manufacturing...

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression...

Precision Formulation in Personalized Medicine

Personalized Medicine and the Future of Precision Formulation The medical...

The European Medicines Agency (EMA) has approved Genzyme’s manufacturing plant in Framingham, Massachusetts, US for the production of Fabrazyme (agalsidase beta).

Fabrazyme (agalsidase beta) is used to treat patients with Fabry disease. Fabrazyme lowers the amount of a substance called globotriaosylceramide (GL-3), which builds up in cells lining the blood vessels of the kidney and certain other cells.

According to Genzyme, the complete return to normal supply levels of Fabrazyme globally will not be immediate due to production lead times and pending regulatory approvals.

Genzyme president and CEO David Meeker said the approval by the EMA represents an important milestone in their manufacturing recovery and path toward unconstrained supply for all patients.

“Providing the Fabry community with consistent access to treatment, increasing our inventory of Fabrazyme and working toward all regulatory approvals of our Framingham plant are our highest priorities,” Meeker added.

Latest stories

Related stories

LTS Grows U.S. Footprint by Buying CDMO Renaissance Lakewood

As the U.S. production investments continue to roll in...

AstraZeneca Plant Expansion to Double Production of Lokelma

AstraZeneca has gone on to announce a newly expanded manufacturing...

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression...

Precision Formulation in Personalized Medicine

Personalized Medicine and the Future of Precision Formulation The medical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »